Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes

Ji Young Yoon, Hyuck Hoon Kwon, Seong Uk Min, Diane M. Thiboutot, Dae Hun Suh

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Acne vulgaris is a highly prevalent skin disorder characterized by hyperseborrhea, inflammation, and Propionibacterium acnes overgrowth. Only isotretinoin and hormonal therapy reduce sebum production. To identify a new drug candidate that modulates sebum, we examined the effects of EGCG, the major polyphenol in green tea, on human SEB-1 sebocytes and in patients with acne. In SEB-1 sebocytes, we found that EGCG reduced sebum by modulating the AMPK-SREBP-1 signaling pathway. EGCG also reduces inflammation by suppressing the NF-κB and AP-1 pathways. EGCG also induces cytotoxicity of SEB-1 sebocytes via apoptosis and decreases the viability of P. acnes, thus targeting almost all the pathogenic features of acne. Finally, and most importantly, EGCG significantly improved acne in an 8-week randomized, split-face, clinical trial, and was well tolerated. Our data provide a therapeutic rationale for the use of EGCG in acne.

Original languageEnglish (US)
Pages (from-to)429-440
Number of pages12
JournalJournal of Investigative Dermatology
Volume133
Issue number2
DOIs
StatePublished - Jan 1 2013

Fingerprint

Isotretinoin
AMP-Activated Protein Kinases
Transcription Factor AP-1
Acne Vulgaris
Polyphenols
Cytotoxicity
Sebum
Skin
Apoptosis
Propionibacterium acnes
Pharmaceutical Preparations
Inflammation
Therapeutic Uses
Tea
epigallocatechin gallate
Clinical Trials

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Molecular Biology
  • Dermatology
  • Cell Biology

Cite this

@article{1c0c3d9619be42ad98e4c37ce2fdb3ff,
title = "Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes",
abstract = "Acne vulgaris is a highly prevalent skin disorder characterized by hyperseborrhea, inflammation, and Propionibacterium acnes overgrowth. Only isotretinoin and hormonal therapy reduce sebum production. To identify a new drug candidate that modulates sebum, we examined the effects of EGCG, the major polyphenol in green tea, on human SEB-1 sebocytes and in patients with acne. In SEB-1 sebocytes, we found that EGCG reduced sebum by modulating the AMPK-SREBP-1 signaling pathway. EGCG also reduces inflammation by suppressing the NF-κB and AP-1 pathways. EGCG also induces cytotoxicity of SEB-1 sebocytes via apoptosis and decreases the viability of P. acnes, thus targeting almost all the pathogenic features of acne. Finally, and most importantly, EGCG significantly improved acne in an 8-week randomized, split-face, clinical trial, and was well tolerated. Our data provide a therapeutic rationale for the use of EGCG in acne.",
author = "Yoon, {Ji Young} and Kwon, {Hyuck Hoon} and Min, {Seong Uk} and Thiboutot, {Diane M.} and Suh, {Dae Hun}",
year = "2013",
month = "1",
day = "1",
doi = "10.1038/jid.2012.292",
language = "English (US)",
volume = "133",
pages = "429--440",
journal = "Journal of Investigative Dermatology",
issn = "0022-202X",
publisher = "Nature Publishing Group",
number = "2",

}

Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes. / Yoon, Ji Young; Kwon, Hyuck Hoon; Min, Seong Uk; Thiboutot, Diane M.; Suh, Dae Hun.

In: Journal of Investigative Dermatology, Vol. 133, No. 2, 01.01.2013, p. 429-440.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Epigallocatechin-3-gallate improves acne in humans by modulating intracellular molecular targets and inhibiting P. acnes

AU - Yoon, Ji Young

AU - Kwon, Hyuck Hoon

AU - Min, Seong Uk

AU - Thiboutot, Diane M.

AU - Suh, Dae Hun

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Acne vulgaris is a highly prevalent skin disorder characterized by hyperseborrhea, inflammation, and Propionibacterium acnes overgrowth. Only isotretinoin and hormonal therapy reduce sebum production. To identify a new drug candidate that modulates sebum, we examined the effects of EGCG, the major polyphenol in green tea, on human SEB-1 sebocytes and in patients with acne. In SEB-1 sebocytes, we found that EGCG reduced sebum by modulating the AMPK-SREBP-1 signaling pathway. EGCG also reduces inflammation by suppressing the NF-κB and AP-1 pathways. EGCG also induces cytotoxicity of SEB-1 sebocytes via apoptosis and decreases the viability of P. acnes, thus targeting almost all the pathogenic features of acne. Finally, and most importantly, EGCG significantly improved acne in an 8-week randomized, split-face, clinical trial, and was well tolerated. Our data provide a therapeutic rationale for the use of EGCG in acne.

AB - Acne vulgaris is a highly prevalent skin disorder characterized by hyperseborrhea, inflammation, and Propionibacterium acnes overgrowth. Only isotretinoin and hormonal therapy reduce sebum production. To identify a new drug candidate that modulates sebum, we examined the effects of EGCG, the major polyphenol in green tea, on human SEB-1 sebocytes and in patients with acne. In SEB-1 sebocytes, we found that EGCG reduced sebum by modulating the AMPK-SREBP-1 signaling pathway. EGCG also reduces inflammation by suppressing the NF-κB and AP-1 pathways. EGCG also induces cytotoxicity of SEB-1 sebocytes via apoptosis and decreases the viability of P. acnes, thus targeting almost all the pathogenic features of acne. Finally, and most importantly, EGCG significantly improved acne in an 8-week randomized, split-face, clinical trial, and was well tolerated. Our data provide a therapeutic rationale for the use of EGCG in acne.

UR - http://www.scopus.com/inward/record.url?scp=84872608286&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84872608286&partnerID=8YFLogxK

U2 - 10.1038/jid.2012.292

DO - 10.1038/jid.2012.292

M3 - Article

C2 - 23096708

AN - SCOPUS:84872608286

VL - 133

SP - 429

EP - 440

JO - Journal of Investigative Dermatology

JF - Journal of Investigative Dermatology

SN - 0022-202X

IS - 2

ER -